SCHEMBL23928147

SCHEMBL23928147

NCCc1ccc(NC(=O)CN2CCCC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
ALDH1A1 P00352 4/20 0.64
THRB P10828 1/20 0.64
HPGD P15428 2/20 0.62
HTT P42858 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
HRH3 Q9Y5N1 1/20 0.61
NPC1 O15118 3/20 0.61
TP53 P04637 1/20 0.61
RAB9A P51151 1/20 0.61
USP2 O75604 1/20 0.60
LMNA P02545 1/20 0.58
POLB P06746 2/20 0.57
GAA P10253 1/20 0.57
MAPT P10636 1/20 0.57
RAD52 P43351 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23963263 0.87 HRH3 (0.68) KDM4EALDH1A1HPGDTDP1HRH3
SCHEMBL23963222 0.87 LMNA (0.60) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL4218487 0.87 ATM (0.64) ALDH1A1MEN1KMT2ANPC1TP53
SCHEMBL21834098 0.87 KDM4E (0.66) KDM4EALDH1A1THRBHPGDHTT
SCHEMBL23928157 0.86 SMYD3 (0.53) KDM4EALDH1A1THRBHPGDHTT
SCHEMBL23291376 0.86 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ALMNAPOLB
SCHEMBL23928233 0.85 HRH3 (0.52) KDM4EALDH1A1THRBHPGDHTT
SCHEMBL1409462 0.84 KDM4E (0.71) KDM4EALDH1A1THRBHPGDHTT
SCHEMBL6279470 0.84 KDM4E (0.71) KDM4EALDH1A1THRBHPGDHTT
SCHEMBL22407743 0.83 KDM4E (0.69) KDM4EALDH1A1THRBHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 EP disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 CN disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
CN-111051309-A Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2020-04-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 KDM4E 3952/4885ALDH1A1 571/4885THRB 162/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 KDM4E 3952/4885ALDH1A1 571/4885THRB 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.